SunTrust Robinson Humphrey (STRH) continues to expand its Equity Research team with the hiring of four experienced analysts covering the biotechnology and medical device industries. These additions bolster STRH’s research expertise and capability, and are a key part of the industry-leading content aggregation within Equity Research.

“The healthcare sector, particularly the biotechnology and medical device industries, remain strong growth areas for the U.S. economy and of the utmost interest to our institutional client base. We’re investing in industry-leading talent to serve the needs of existing and prospective clients. We are very pleased to welcome these teammates, who have a broad range of financial services and industry experience,” said Robert Popowski, managing director and head of Sales, Trading & Research at STRH.

Bruce Nudell joins STRH as a managing director, responsible for coverage of the Medical Device sector, based in Atlanta. Nudell is a revered industry expert, as he has more than 14 years of Wall Street experience as a senior publishing research analyst, as well as 18 years of corporate experience in strategic planning and project management roles working within science and medical labs.

Peter Lawson joins STRH as a director covering Biotech. Lawson was most recently a senior healthcare analyst at Mizuho Securities, where he covered both Biotechnology and the Diagnostic Tools areas. His prior experience includes six years at Thomas Weisel Partners, where he covered Healthcare Tools and Diagnostics, initially as an associate and eventually as a senior analyst.

Yatin Suneja joins STRH as a director providing Biotech research coverage. Suneja was most recently at Cowen and Company, where he spent the last four years covering Biotech stocks. Prior to Cowen, he was a key member of the Biotech team at Rodman & Renshaw, where he covered a broad range of companies, wrote influential white papers on key therapeutic categories, and supported the build out of that firm’s Biotech practice. Imron Zafar joins STRH as a vice president covering the Medical Devices and Technology space. Zafar brings 15 years of sell-side equity research experience. For the past five years, he was a member of the Medical Devices and Technology team at Jefferies and Company, covering over 35 stocks in multiple therapeutic areas and market caps. Previously he worked with the Med Tech team at Deutsche Bank for seven years and with the Chemicals team at Credit Suisse First Boston.

“The healthcare sector, particularly the biotechnology and medical device industries, remain strong growth areas for the U.S. economy and of the utmost interest to our institutional client base. We’re investing in industry-leading talent to serve the needs of existing and prospective clients. We are very pleased to welcome these teammates, who have a broad range of financial services and industry experience,” said Robert Popowski, managing director and head of Sales, Trading & Research at STRH.